In 2020, the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) published a recommendation to screen for DPD deficiency in cancer patients either by DPYD genotyping or DPD phenotyping before the use of FP (EMA, 2020; EMA, 2022). Here, DPYD is linked to cancer.